VYNE (VYNE Therapeutics) FFO


VYNE VYNE Therapeutics Inc VYNE
37 GF Score
Price $0.65
GF Value $0.55
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is VYNE Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

VYNE
37GF Score
VYNE Therapeutics Inc VYNE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VYNE Therapeutics (VYNE) Overvalued in 2026?

Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued. The current stock price of $0.65 is trading 17.9% above its estimated GF Value™ of $0.55. GuruFocus considers VYNE Therapeutics to be Modestly Overvalued.

Key valuation signals for VYNE:

  • FFO:
  • GF Value™: $0.55 vs. price of $0.65 (17.9% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VYNE Therapeutics Business Description

Address P.O. Box 125, Stewartsville, NJ, USA, 08886
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
37GF Score

Get the complete analysis for VYNE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.55
GF Value